Communicating the Risk of Death from Novel Coronavirus Disease (COVID-19)
- PMID: 32098019
- PMCID: PMC7073841
- DOI: 10.3390/jcm9020580
Communicating the Risk of Death from Novel Coronavirus Disease (COVID-19)
Abstract
To understand the severity of infection for a given disease, it is common epidemiological practice to estimate the case fatality risk, defined as the risk of death among cases. However, there are three technical obstacles that should be addressed to appropriately measure this risk. First, division of the cumulative number of deaths by that of cases tends to underestimate the actual risk because deaths that will occur have not yet observed, and so the delay in time from illness onset to death must be addressed. Second, the observed dataset of reported cases represents only a proportion of all infected individuals and there can be a substantial number of asymptomatic and mildly infected individuals who are never diagnosed. Third, ascertainment bias and risk of death among all those infected would be smaller when estimated using shorter virus detection windows and less sensitive diagnostic laboratory tests. In the ongoing COVID-19 epidemic, health authorities must cope with the uncertainty in the risk of death from COVID-19, and high-risk individuals should be identified using approaches that can address the abovementioned three problems. Although COVID-19 involves mostly mild infections among the majority of the general population, the risk of death among young adults is higher than that of seasonal influenza, and elderly with underlying comorbidities require additional care.
Keywords: emerging infectious diseases; fatality; statistical estimation; virulence; virus.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- European Centre for Disease Prevention and Control “Situation Update—Worldwide”. [(accessed on 13 February 2020)];2020 Available online: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.
Publication types
Grants and funding
- JP18fk0108050/Japan Agency for Medical Research and Development
- H.N.: 17H04701, 17H05808, 18H04895 and 19H01074; R.K.: 18J21587, AS.: 19K24159/Japan Society for the Promotion of Science
- NA/Inamori Foundation
- JPMJCR1413/Core Research for Evolutional Science and Technology
- NA/Ministry of Education, Culture, Sports, Science and Technology
LinkOut - more resources
Full Text Sources
Medical